clarithromycin has been researched along with cem 101 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Castanheira, M; Jones, RN; Woosley, LN | 1 |
Higuchi, K; Inoue, K; Kishimoto, H; Kiyomiya, K; Saito, N; Shirasaka, Y; Takada, T; Tomabechi, R; Watai, K | 1 |
2 other study(ies) available for clarithromycin and cem 101
Article | Year |
---|---|
CEM-101 activity against Gram-positive organisms.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Clarithromycin; Drug Resistance, Bacterial; Drug Synergism; Erythromycin; Gentamicins; Gram-Positive Bacteria; Ketolides; Macrolides; Microbial Sensitivity Tests; Ofloxacin; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae; Streptococcus pyogenes; Triazoles; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin | 2010 |
Macrolide and Ketolide Antibiotics Inhibit the Cytotoxic Effect of Trastuzumab Emtansine in HER2-Positive Breast Cancer Cells: Implication of a Potential Drug-ADC Interaction in Cancer Chemotherapy.
Topics: Ado-Trastuzumab Emtansine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azithromycin; Breast Neoplasms; Clarithromycin; Female; Humans; Immunoconjugates; Ketolides; Lysosomes; Maytansine; Receptor, ErbB-2; Trastuzumab | 2023 |